Raz Winiarsky, MD
Orthopaedic Surgery of the Spine · Brooklyn, NYNPI 1992769061
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $72,660 of the $74,554 with a category attached, or 97.5%. Royal Biologics, Inc. accounts for 97.5% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2024 at $68,501 and has fallen 93.3% since, to $4,622 in 2025.
Across 87 payments — averaging $856.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Royal Biologics, Inc.$73K
- Fidia Pharma USA Inc.$342
- Smith+Nephew$286
- Amgen$255
- Stryker$146
- Vertex$126
- plus $739 from 18 others
What the payments were for
- Consulting fees$72,66097%
- Food & beverage$1,8943%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Royal Biologics, Inc. | 14 | $72,660 |
| Fidia Pharma USA Inc. | 17 | $342 |
| Smith+Nephew | 7 | $286 |
| Amgen | 17 | $255 |
| Stryker | 2 | $146 |
| Vertex | 5 | $126 |
| Eisai Inc. | 1 | $125 |
| Zimmer Biomet | 2 | $112 |
| Orthofix Medical, Inc. | 3 | $89 |
| Arteriocyte Medical Systems, Inc. | 1 | $89 |
| Saluda Medical Americas, Inc. | 2 | $54 |
| Ferring Pharmaceuticals Inc. | 2 | $38 |
| Valinor Pharma, LLC | 2 | $35 |
| DJO, LLC | 1 | $30 |
| Endo Pharmaceuticals Inc. | 2 | $27 |
| Axogen | 1 | $24 |
| Bioventus LLC | 1 | $22 |
| AbbVie | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $16 |
| Zyla Life Sciences, Inc. | 1 | $15 |
| Seapearl East, Inc | 1 | $14 |
| Pacira Pharmaceuticals Incorporated | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
| Trice Medical, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$74,554 in reported general payments places this provider in the 75th percentile of 161 orthopaedic surgery of the spine providers in New York.
See all orthopaedic surgery of the spine providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine | 180 | $19,418 |
| Diclofenac Sodium | 167 | $15,614 |
| Diclofenac Epolamine | 27 | $12,963 |
| MovantikNaloxegol Oxalate | 66 | $6,514 |
| Enoxaparin Sodium | 42 | $3,746 |
| Meloxicam | 232 | $831 |
| Naproxen | 80 | $481 |
| Cephalexin | 16 | $468 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 80 | $423 |
| Ibuprofen | 43 | $357 |
| Ondansetron Hcl | 75 | $252 |
| Celecoxib | 19 | $136 |
| Cyclobenzaprine Hcl | 21 | $102 |
| Tizanidine Hcl | 25 | $68 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 11 | $59 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Redhill Biopharma Inc.Movantik | $16 | $6,51466 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 161 orthopaedic surgery of the spine providers in New York.
Other orthopaedic surgery of the spine in Brooklyn
- Michael GerlingBrooklyn$96K
- Dante LevenBrooklyn$36K
- Joseph PyunBrooklyn$24K
- Hansen YuanSyracuse$31.7M
- Frank SchwabNew York$5.1M
- Han KimNew York$3.9M
- Todd AlbertNew York$2.7M
- Jeffrey SpivakNew York$1.3M
- Aaron BucklandNew York$1M
- Seth NeubardtWhite Plains$902K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.